Drugs / Recombinant Human Keratinocyte Growth Factor
Recombinant Human Keratinocyte Growth Factor
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00056875 | Sep 2002 → Jun 2005 | graft versus host disease | University of Michigan | Completed | No outcome recorded |
| Phase 1/2 | NCT00038792 | Oct 2000 → Jan 2003 | acute graft versus host disease | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00041665 | — | stomatitis | Amgen | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant human keratinocyte growth factor | “A double-blind, randomized trial showed that, compared with placebo, palifermin (recombinant human keratinocyte growth factor) reduced the frequency and duration of oral...” PMID 17580258 ↗ Apr 2007 |
| Modality | Protein / enzyme biologic | “recombinant human keratinocyte growth factor” NCT00038792 ↗ |
| Route | Intravenous | “106 patients received palifermin (60 microg per kilogram of body weight per day) and 106 received a placebo intravenously for three consecutive days immediately before the...” PMID 15602019 ↗ Dec 2004 |